RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
Affiliation
The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M204BX,Issue Date
2020
Metadata
Show full item recordAbstract
NoneCitation
Howell SJ, Keevil B, Higham C, Owen LJ, Monaghan PJ. RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer. Eur J Cancer. 2020;136:204-5.Journal
European Journal of CancerDOI
10.1016/j.ejca.2020.04.050PubMed ID
32665169Additional Links
https://dx.doi.org/10.1016/j.ejca.2020.04.050Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2020.04.050
Scopus Count
Collections
Related articles
- Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
- Authors: Samuel E, Chiang C, Jennens R, Faulkner D, Francis PA
- Issue date: 2020 Sep
- Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
- Authors: Samuel E, Chiang C, Jennens R, Faulkner D, Francis PA
- Issue date: 2020 Feb
- Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
- Authors: McKeage K, Curran MP, Plosker GL
- Issue date: 2004
- Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
- Authors: Gradishar W
- Issue date: 2005 Jun
- Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
- Authors: Raina V
- Issue date: 2004 Nov